Skip to main content
SpringerLink
Log in

Ulotaront − exploring the safety profile of a novel treatment for schizophrenia

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Sunovion Pharmaceuticals Inc.

Reference

  • Hopkins SC, et al. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clinical Drug Investigation : 9 Nov 2021. Available from: URL: http://doi.org/10.1007/s40261-021-01094-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ulotaront − exploring the safety profile of a novel treatment for schizophrenia. Reactions Weekly 1882, 12 (2021). https://doi.org/10.1007/s40278-021-05479-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-05479-5

Search

Navigation